What Else Analysts Want To Know About Phase III Data For TMC’s Inclisiran

 
• By Joseph Haas

Looking to be a game-changer with a highly effective LDL-C-lowering agent dosed twice annually, The Medicines Company says inclisiran met efficacy endpoints in a large Phase III study. But observers await fuller data, including safety details.

LDL (Bad) Cholesterol level chart on a table. - Image
TMC hopes inclisiran can reduce LDL-C levels with twice-annual dosing

More from Clinical Trials

More from R&D